¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"pattern dystrophy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • male pattern baldness
    ³²¼ºÇü´ë¸Ó¸®
  • occlusal pattern
    ±³ÇÕ¾ç»ó, ¸Â¹°¸²¾ç»ó
  • pattern
    ¾ç»ó, ¾ç½Ä, ¸ð¾ç, ÆÐÅÏ
  • pattern recognition
    ÆÐÅÏÀνÄ, ¸ð¾çÀνÄ
  • recruitment pattern
    Á¡Áõ¾ç»ó
  • semiliquid echo pattern
    ¹Ý¾×ü¿¡ÄÚ¾ç»ó
  • single interference pattern
    ´ÜÀϰ£¼·¾ç»ó
  • sinusoidal pattern
    ±¼¸ð¾çÆÐÅÏ
  • ventilatory pattern
    ȯ±â¾ç»ó
  • wax pattern
    ³³Çü, ¹Ð³³Çü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • occlusal pattern
    ±³ÇÕ¸éÇüÅÂ, ¸Â¹°¸²¸éÇüÅÂ
  • pattern
    ¾ç½Ä, ÆÐÅÏ, ¸ð¾ç
  • pattern recognition
    ÆÐÅÏÀνÄ, ¸ð¾çÀνÄ
  • recruitment pattern
    Á¡Áõ¾ç»ó
  • semiliquid echo pattern
    ¹Ý¾×ü¿¡ÄÚ¾ç»ó
  • single interference pattern
    ´ÜÀϰ£¼·¾ç»ó
  • ventilatory pattern
    ȯ±â¾ç»ó
  • wax pattern
    ³³Çü, ¹Ð³³Çü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • male pattern baldness
    ³²¼ºÇü´ë¸Ó¸®(Áõ)
  • male pattern baldness
    ³²¼ºÇü´ë¸Ó¸®(Áõ)(Ñûàõúþñø).
  • millimeter pattern
    ¹Ð¸®¹ÌÅÍ ¾ç»ó
  • mixed pattern
    È¥ÇÕ ¾ç»ó
  • mosaic pattern
    ¸ðÀÚÀÌÅ©¸ðÇü(¡­Ù¼úþ).
  • mosaic pattern
    ¸ðÀÚÀÌÅ© ¾ç»ó
  • muscle pattern
    ±Ù(¹ÝÀÀ)»ó(ÐÉÚãëëßÀ).
  • nodular pattern
    ¼Ò°áÀý ¾ç»ó
  • occlusal pattern
    ±³ÇÕ¸éÇüÅÂ(ÎáùêØüû¡÷¾).
  • optokinetic pattern
    ½Ã¿îµ¿ÆÐÅÏ.
  • pattern
    ¸ð¾ç(Ù¼åÆ), ¾ç½Ä(åÆãÒ), ÆÐÅÏ.
  • pattern of failure
    Àç¹ß¾ç»ó
  • pattern recognition
    ÆÐÅÏÀνÄ
  • pattern recognition
    ÆÐÅÏÀνÄ, ¸ð¾çÀνÄ.
  • pedigree pattern of autosomal dominant trait
    »ó¿°»öü¼º ¿ì¼ºÇüÁúÀÇ °¡°èµµ(ßÈæøßäô÷àõéÐàõû¡òõ¡­Ê«Í§Óñ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CLIP capitolunate instability pattern; corticotropin-like intermediate lobe peptide
Dp pattern difference
EEGV1 electroencephalographic variant pattern 1
MCP maximum closure pressure; maximum contraction pattern; malanocortin receptor; melphalan, cyclophosph...
MCPP metacarpophalangeal pattern profile; metacarpophalangeal profile; meta-chlorophenylpiperazine
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PVEP Pattern Visual Evoked Potential
PERG Pattern-reversal electroretinograms
pVEP Pattern reversal visual evoked potentials
SPAQ Seasonal Pattern Assessment Questionnaire
SDP strain distribution pattern
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • nodular pattern
    ¼Ò°áÀý ¾ç»ó
  • optokinetic pattern test
    ½Ã ¿îµ¿ ÆÐÅÏ °Ë»ç
  • pattern of inheritance
    À¯Àü Çü½Ä
  • pedigree pattern of autosomal dominant trait
    »ó¿°»öü¼º ¿ì¼º ÇüÁúÀÇ °¡°èµµ
  • string of beads pattern
    ¿°ÁÖ ¸ð¾ç
  • terminal pattern
    ¸»´Ü ÇüÅÂ
  • tongue-thrust pattern
    ¼³ µ¹Ãâ ¾ç»ó
  • wax pattern taking
    ³³Çü 䵿
  • zigzag pattern
    Áö±×Àç±× ÇüÅÂ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
juvenile pattern A precordial T-wave inversion, sometimes with J-ST elevations in an electrocardiogram, resembling that seen in normal children, which occurs as a normal variant in some adults, especially blacks, and especially in leads V1, V2, and V3.
(05 Mar 2000)
female pattern alopecia Diffuse partial hair loss in the centroparietal area of the scalp, with preservation of the frontal and temporal hair lines; the most frequent type of androgenic alopecia in women.
(05 Mar 2000)
female pattern baldness <dermatology> Hair loss in women that may be associated with aging, hormones (androgens) or genetic predisposition.
The pattern of baldness in women is different from that of men. In women there is thinning of the hair all over the scalp, but the frontal hairline is maintained. The hair loss is usually permanent. Treatment has been successful with topical minoxidil in some cases.
(27 Sep 1997)
adiposogenital dystrophy A disorder characterised primarily by obesity and hypogonadotrophic hypogonadism in adolescent boys; dwarfism is rare, and when present is thought to reflect hypothyroidism. Visual loss, behavioural abnormalities, and diabetes insipidus may occur. Frohlich's syndrome often is used synonymously for this disorder, although the original case involved a pituitary tumour; most cases are thought to result from hypothalamic dysfunction in areas regulating appetite and gonadal development. The most common causes are pituitary and hypothalamic neoplasms.
Synonym: adiposis orchica, adiposogenital degeneration, adiposogenital dystrophy, adiposogenital syndrome, hypophysial syndrome, hypothalamic obesity with hypogonadism.
Origin: L. Fr. G. Dys-, bad, + trophe, nourishment
(05 Mar 2000)
adult pseudohypertrophic muscular dystrophy Muscular dystrophy of late onset, often in the second or third decade, with relatively mild course; X-linked recessive inheritance; perhaps allelic with Duchenne's dystrophy, but milder and not a genetic lethal.
Compare: Duchenne dystrophy.
Synonym: Becker type tardive muscular dystrophy.
(05 Mar 2000)
Barnes' dystrophy A rare type of muscular dystrophy, in which muscles are often hypertrophic and stronger than normal, but later become weak and atrophic.
(05 Mar 2000)
Becker's muscular dystrophy An X-linked inherited disorder characterised by slowly progressive muscle weakness of the legs and pelvis. Other symptoms and findings include increased difficulty walking, intellectual retardation, fatigue and pseudohypertrophy of the calf muscles.
(27 Sep 1997)
Becker type muscular dystrophy A muscular dystrophy that has many of the clinical features of Duchenne muscular dystrophy e.g., symmetrical involvement of first the pelvicrural muscles and then the pectoral girdle and proximal upper extremity muscles; pseudohypertrophy, especially of the calf muscles but with a much later age of onset (35-45 years), and more benign course. X-linked inheritance.
(05 Mar 2000)
Becker type tardive muscular dystrophy Muscular dystrophy of late onset, often in the second or third decade, with relatively mild course; X-linked recessive inheritance; perhaps allelic with Duchenne's dystrophy, but milder and not a genetic lethal.
Compare: Duchenne dystrophy.
Synonym: Becker type tardive muscular dystrophy.
(05 Mar 2000)
benign pseudohypertrophic muscular dystrophy <neurology> An X-linked inherited disorder characterised by slowly progressive muscle weakness of the legs and pelvis. Other symptoms and findings include increased difficulty walking, intellectual retardation, fatigue and pseudohypertrophy of the calf muscles.
(06 Aug 1998)
macular dystrophy A group of disorders involving predominately the posterior portion of the ocular fundus, due to degeneration in the sensory layer of the retina, retinal pigment epithelium, Bruch's membrane, choroid, or a combination of these tissues.
See: Stargardt's disease, Best's disease.
(05 Mar 2000)
map-dot-fingerprint dystrophy Fingerprint dystrophy accompanied by map-like patterns and microcystic epithelial inclusions.
(05 Mar 2000)
reflex sympathetic dystrophy A syndrome of pain and tenderness, usually to a hand or foot, associated with vasomotor instability, skin changes and rapid development of bony demineralisation (osteoporosis). Frequently will follow a localised trauma, stroke or peripheral nerve injury.
(27 Sep 1997)
reflex sympathetic dystrophy syndrome <syndrome> A condition that features a group of typical symptoms, including pain (often burning type), tenderness, and swelling of an extremity associated with varying degrees of sweating, warmth and/or coolness, flushing, discoloration, and shiny skin.
(12 Dec 1998)
vitreo-tapetoretinal dystrophy Autosomal recessive bilateral peripheral and central retinoschisis with pigmentary degeneration of the retina, chorioretinal atrophy, vitreous degeneration, and night blindness.
Synonym: Favre's dystrophy.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á